A phase 3 trial demonstrates that aficamten improves oxygen utilization during exercise for obstructive HCM patients, indicating its potential to enhance daily functionality and quality of life.

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.

Teclistamab, a BCMA bispecific antibody, demonstrates a promising 63% overall response rate in heavily pretreated R/R MM patients, with manageable toxicity compared to CAR T-cell therapy.

A Swedish case-control study identified a 21% increased risk of malignant lymphoma in individuals with tattoos compared to controls, prompting the need for further research into tattoo ink composition and potential long-term health effects.

IL-1B significantly influences breast cancer bone metastasis by promoting EMT, enhancing osteoclast activity, and creating a conducive metastatic niche. Targeting IL-1B in combination with standard therapies shows promising potential to reduce metastatic outgrowth.

Pirtobrutinib offers a new line of therapy for CLL and SLL patients who have progressed after covalent BTK inhibitors and venetoclax, with a significant overall response rate and manageable adverse events.